1-4 of 4
Zhaoyang Teng, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Meletios A Dimopoulos, MD, Francesca Gay, MDPhD, Fredrik H. Schjesvold, MDPhD, Meral Beksac, MD, Roman Hajek, Katja Weisel, MD, Hartmut Goldschmidt, MD, Vladimir Maisnar, MD, Philippe Moreau, Chang-Ki Min, MD PhD, Agnieszka Pluta, MD, Wee Joo Chng, MB ChB, PhD FRCP(UK), FRCPath, FAMS, Martin Kaiser, MD, Sonja Zweegman, MDPhD, Maria-Victoria Mateos, MD PhD, Andrew Spencer, MBBS, FRACP, FRCPA, DM, Shinsuke Iida, MDPhD, Gareth Morgan, MD, Zhaoyang Teng, PhD, Kaveri Suryanarayan, MD, Tomas Skacel, MD PhD, Ajeeta B Dash, PhD, Richard Labotka, MD, S. Vincent Rajkumar, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 301.
https://doi.org/10.1182/blood-2018-99-112079
Published: 2018
Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 902.
https://doi.org/10.1182/blood.V130.Suppl_1.902.902
Published: 2017
Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos
Journal: Blood
Blood (2016) 128 (22): 3327.
https://doi.org/10.1182/blood.V128.22.3327.3327
Published: 2016
Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD
Journal: Blood
Blood (2015) 126 (23): 26.
https://doi.org/10.1182/blood.V126.23.26.26
Published: 2015